Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on developing antibody treatments for Inflammatory Bowel Disease (IBD) and other immune-mediated diseases, has announced its participation in two major healthcare investor conferences in June 2025.
The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 8:10am ET, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 9:20am ET. Live webcasts and replays will be accessible through Spyre's investor relations website.
Spyre Therapeutics (NASDAQ: SYRE), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di trattamenti con anticorpi per la Malattia Infiammatoria Intestinale (IBD) e altre patologie immuno-mediate, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a giugno 2025.
L'azienda presenterà al Jefferies Global Healthcare Conference il 4 giugno 2025 alle 8:10 ET, e al Goldman Sachs 46th Annual Global Healthcare Conference il 9 giugno 2025 alle 9:20 ET. Le dirette streaming e le registrazioni saranno disponibili sul sito web delle relazioni con gli investitori di Spyre.
Spyre Therapeutics (NASDAQ: SYRE), una empresa biotecnológica en fase clínica enfocada en desarrollar tratamientos con anticuerpos para la Enfermedad Inflamatoria Intestinal (EII) y otras enfermedades mediadas por el sistema inmunológico, ha anunciado su participación en dos importantes conferencias para inversores del sector salud en junio de 2025.
La compañía presentará en la Jefferies Global Healthcare Conference el 4 de junio de 2025 a las 8:10 am ET, y en la Goldman Sachs 46th Annual Global Healthcare Conference el 9 de junio de 2025 a las 9:20 am ET. Las transmisiones en vivo y las repeticiones estarán disponibles a través del sitio web de relaciones con inversores de Spyre.
Spyre Therapeutics (NASDAQ: SYRE)는 염증성 장 질환(IBD) 및 기타 면역 매개 질환 치료용 항체 개발에 주력하는 임상 단계 바이오테크 회사로, 2025년 6월 두 개의 주요 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 2025년 6월 4일 오전 8시 10분(동부시간)에 Jefferies Global Healthcare Conference에서, 2025년 6월 9일 오전 9시 20분(동부시간)에 Goldman Sachs 46th Annual Global Healthcare Conference에서 발표할 예정입니다. 실시간 웹캐스트와 다시보기는 Spyre의 투자자 관계 웹사이트를 통해 제공됩니다.
Spyre Therapeutics (NASDAQ : SYRE), une société biotechnologique en phase clinique spécialisée dans le développement de traitements par anticorps pour la maladie inflammatoire de l'intestin (MII) et d'autres maladies immunitaires, a annoncé sa participation à deux grandes conférences pour investisseurs dans le domaine de la santé en juin 2025.
La société présentera lors de la Jefferies Global Healthcare Conference le 4 juin 2025 à 8h10 ET, ainsi qu'à la Goldman Sachs 46th Annual Global Healthcare Conference le 9 juin 2025 à 9h20 ET. Les webdiffusions en direct et les replays seront accessibles via le site des relations investisseurs de Spyre.
Spyre Therapeutics (NASDAQ: SYRE), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Antikörpertherapien für entzündliche Darmerkrankungen (IBD) und andere immunvermittelte Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Gesundheitsinvestorenkonferenzen im Juni 2025 angekündigt.
Das Unternehmen wird am Jefferies Global Healthcare Conference am 4. Juni 2025 um 8:10 Uhr ET sowie am Goldman Sachs 46th Annual Global Healthcare Conference am 9. Juni 2025 um 9:20 Uhr ET präsentieren. Live-Webcasts und Aufzeichnungen sind über die Investor-Relations-Website von Spyre zugänglich.
- None.
- None.
Event: Jefferies Global Healthcare Conference
Date: Wednesday, June 4, 2025
Fireside Time: 8:10am ET
Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Date: Monday, June 9, 2025
Fireside Time: 9:20am ET
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-june-investor-conferences-302464699.html
SOURCE Spyre Therapeutics, Inc.
FAQ
What investor conferences will Spyre Therapeutics (SYRE) attend in June 2025?
What time is Spyre Therapeutics' (SYRE) presentation at the Jefferies Healthcare Conference?
What is Spyre Therapeutics' (SYRE) main focus area for drug development?
Where can investors watch Spyre Therapeutics' (SYRE) conference presentations?
